非酒精性脂肪性肝病与动脉粥样硬化*

doi:10.3969/j.issn.1672-5069.2017.03.003

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (3): 263-266.doi: 10.3969/j.issn.1672-5069.2017.03.003

非酒精性脂肪性肝病与动脉粥样硬化^*

何方平

830054 乌鲁木齐市新疆医科大学第一附属医院肝病科

收稿日期:2017-03-06 出版日期:2017-06-10 发布日期:2018-03-10
作者简介:何方平,女,医学博士,主任医师,教授,博士研究生导师。中华医学会内分泌学分会“肝病与代谢”学组委员,致力于非传染性肝病尤其是代谢性肝病、肝硬化和肝细胞癌的临床研究。E-mail:hefp@sina.com
基金资助:
*国家自然科学基金资助项目 (编号：81360138)

Atherosclerosis in patients with nonalcoholic fatty liver disease

He Fangping

Department of Liver Disease,First Affiliated Hospital,Xinjiang Medical University,Urumqi 830011,Xingjiang Autonomous Region, China

Received:2017-03-06 Online:2017-06-10 Published:2018-03-10

摘要/Abstract

关键词: 非酒精性脂肪性肝病, 动脉粥样硬化, 内皮功能, 炎症

Key words: Nonalcoholic fatty liver disease, Atherosclerosis, Endothelial function, Inflammation

何方平. 非酒精性脂肪性肝病与动脉粥样硬化^*[J]. 实用肝脏病杂志, 2017, 20(3): 263-266.

He Fangping. Atherosclerosis in patients with nonalcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 263-266.

[1] Ekstedt M,Franzen LE,Mathiesen UL,et al.Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology,2006,44(4):865-873.
[2] 陈熤. 血小板与动脉粥样硬化. 国际心血管病杂志,2011,38(3):141-144.
[3] 曹一显,李良平. 非酒精性脂肪性肝病与动脉粥样硬化. 国际消化病杂志,2011,31(3):128-131.
[4] Heitzer T,Schlinzig T,Krohn K,et al.Endothelial dysfunction, oxidative stress,and risk of cardiovascular events in patients with coronary artery disease. Circulation,2001,104(22):2673-2678.
[5] 龙盼. 血管内皮功能障碍与动脉粥样硬化. 国际心血管病杂志,2011,38(2):79-81.
[6] Rivera R,Vanaclocha F.Nonalcoholic fatty liver disease and psoriasis. Acta Dermosifiliogr,2010,101(8):657-658.
[7] Ashburn DD,Reed MJ.Gastrointestinal system and obesity. Crit Care Clin,2010,26(4):625-627.
[8] Roitberg GE,Sharkhun OO,Ushakova TI.Non-alcoholic fatty liver disease as an atherosclerosis risk factor. Eksp Klin Gastroenterol,2010,32(7):20-24.
[9] Angulo P,Lindor KD.Insulin resistance and mitochondrial abnormalities in NASH:a cool look into a burning issue. Gastroenterology,2001,120(5):1281-1285.
[10] Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology,2005,42(3):641-649.
[11] 崔晓霞,段桂花,吕井华. 非酒精性脂肪肝与动脉粥样硬化相关的临床研究. 现代保健·医学创新研究,2007,4(11):26-27.
[12] Kessler MA,Levy Y,Roth A,et al.Increased prevalence of NAFLD in patients with acute myoardial infarction independent of BMI. Hepatology,2005,42:623A.
[13] Targher G,Bertolini L,Padovani R,et al.Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med,2006,23(4):403-409.
[14] 高鑫. 非酒精性脂肪性肝病与代谢综合征. 国际内分泌代谢杂志,2006,26(2):73-79.
[15] Las G,Shirihai OS.The role of autophagy in beta-cell lipotoxicity and type 2 diabetes. Diabetes Obes Metab,2010,12(Suppl 2):15-19.
[16] Siddiqui MS,Sterling RK,Luketic VA. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology,2013,145(6):1271-1279. e1-3.
[17] Wang CC,Lin SK,Tseng YF,et al.Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol,2009,24(8):1411-1416.
[18] Ioannou GN,Weiss NS,Boyko EJ,et al.Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology,2006,43(5):1145-1151.
[19] Schindhelm RK,Dekker JM,Nijpels G.Alanine aminotransferase predicts coronary heart disease events:a 10-year follow-up of the Hoorn Study. Atherosclerosis,2007,191(2):391-396.
[20] Goessling W,Massaro JM,Vasan RS,et al.Aminotransferase levels and 20-year risk of metabolic syndrome,diabetes,and cardiovascular disease. Gastroenterology,2008,135(6):1935-1944, 1944. e1.
[21] Wang Z,Nakayama T.Inflammation,a link between obesity and cardiovascular disease. Mediators Inflamm,2010,2010:535918.
[22] de Ferranti S,Mozaffarian D. The perfect storm:obesity,adipocyte dysfunction,and metabolic consequences. Clin Chem,2008,54(6):945-955.
[23] Bakhai A.Adipokines--targeting a root cause of cardiometabolic risk. QJM,2008,101(10):767-776.
[24] Rane SG,Lee JH,Lin HM.Transforming growth factor-beta pathway:role in pancreas development and pancreatic disease. Cytokine Growth Factor Rev,2006,17(1-2):107-119.
[25] Ludmer PL,Selwyn AP,Shook TL,et al.Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med,1986,315(17):1046-1051.
[26] 高浩源. 血管内皮功能检测的研究进展. 现代诊断与治疗, 2011,22(5):289-291,293.
[27] Bonetti PO,Pumper GM,Higano ST,et al.Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol,2004,44(11):2137-2141.
[28] Reisner Y,Lusky R,Shay-EY,et al.Reproducibility of endothelial function and arterial stiffness assessed using finger peripheral arterial tonometry. Eur Heart J,2008,29(6):255-503.
[29] Selamet TES,Newburger JW,Gauvreau K,et al.Endothelial pulse amplitude testing:feasibility and reproducibility in adolescents. J Pediatr,2009,154(6):901-905.

非酒精性脂肪性肝病与动脉粥样硬化^*

Atherosclerosis in patients with nonalcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[3]	汪道伟, 方坚, 范凌. 自身免疫性肝炎患者血清IL-21和趋化因子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 844-847.
[4]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[5]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[6]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[7]	张莹, 王洪岩, 迟程, 徐有青. LPS诱导的HepG2细胞NOTCH与LPS-TLR4-NF-κB炎症信号通路的“会话”研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 470-473.
[8]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[9]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[10]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[11]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[12]	彭小燕,徐莉娟,刘鹏,祁双宝,孙一鸣. 自身免疫性肝炎患者血清腺苷脱氨酶水平与肝组织炎症活动程度的关系及对治疗应答的影响^*[J]. 实用肝脏病杂志, 2019, 22(2): 200-203.
[13]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[14]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[15]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.